The most widely studied strategy for OX40L is OX40 agonist therapy.Preclinical studies demonstrate that OX40 agonists, whether used as monotherapy or in combination, elicit robust antitumor activity in murine tumor models. This evidence concerns the gene TNFRSF4 and neoplasm.